Lilly, Vir, Glaxo Report Positive Topline Data From COVID-19 Trial

 LILLY, VIR BIOTECHNOLOGY AND GSK ANNOUNCE POSITIVE TOPLINE DATA FROM THE PHASE 2 BLAZE-4 TRIAL EVALUATING BAMLANIVIMAB WITH VIR-7831 IN LOW-RISK ADULTS WITH COVID-19

* IN COMBINATION, TWO MONOCLONAL ANTIBODIES DEMONSTRATED A 70% RELATIVE REDUCTION IN PERSISTENTLY HIGH VIRAL LOAD AT DAY 7 COMPARED TO PLACEBO

* NO SERIOUS ADVERSE EVENTS WERE SEEN WITH CO-ADMINISTRATION OF BAMLANIVIMAB AND VIR-7831

* DATA SUGGEST ADMINISTRATION OF BAMLANIVIMAB & VIR-7831 TOGETHER MAY PROVIDE PROTECTION AGAINST CURRENT VARIANTS OF SARS-COV-2 THAT ARE RESISTANT TO BAMLANIVIMAB Source text for Eikon: Further company coverage:

https://www.marketscreener.com/quote/stock/VIR-BIOTECHNOLOGY-INC-66771988/news/Vir-Biotechnology-nbsp-Lilly-Vir-And-GSK-Report-Positive-Topline-Data-From-COVID-19-Trial-Of-Baml-32827533/